Comparative Study
doi: 10.1007/BF01645362.
In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex
Affiliations
- PMID: 1839300
- DOI: 10.1007/BF01645362
Item in Clipboard
Comparative Study
In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex
Infection.
1991 Sep-Oct.
Abstract
The activity of clarithromycin in combination with ethambutol and rifampicin was tested at concentrations achievable in serum against 20 strains of Mycobacterium avium complex. The combination of clarithromycin plus rifampicin showed inhibition of 11 of the strains and bactericidal synergism against seven of the strains. When ethambutol was added, a bactericidal effect was observed against 16 strains. On the basis of these in vitro data it seems that clarithromycin in combination with rifampicin and ethambutol may be a promising drug for the effective treatment of infections caused by M. avium complex.
Similar articles
-
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.Antimicrob Agents Chemother. 1991 Mar;35(3):462-70. doi: 10.1128/AAC.35.3.462. Antimicrob Agents Chemother. 1991. PMID: 1828135 Free PMC article.
-
In-vitro evaluation of clarithromycin, temafloxacin, and ethambutol in combination against Mycobacterium avium complex.J Antimicrob Chemother. 1993 May;31(5):725-30. doi: 10.1093/jac/31.5.725. J Antimicrob Chemother. 1993. PMID: 8392998
-
Efficacy of macrolides used in combination with ethambutol, with or without other drugs, against Mycobacterium avium within human macrophages.Int J Antimicrob Agents. 2001 Dec;18(6):525-30. doi: 10.1016/s0924-8579(01)00461-7. Int J Antimicrob Agents. 2001. PMID: 11738339
-
Combined administration of rifampicin, ethambutol, and clarithromycin for the treatment of tenosynovitis of the hand caused by Mycobacterium avium complex: Case series and literature review.Medicine (Baltimore). 2021 Apr 30;100(17):e25283. doi: 10.1097/MD.0000000000025283. Medicine (Baltimore). 2021. PMID: 33907090 Free PMC article. Review.
-
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.Clin Pharmacokinet. 1997 Feb;32(2):132-44. doi: 10.2165/00003088-199732020-00004. Clin Pharmacokinet. 1997. PMID: 9068928 Review.
Cited by
-
Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.Antimicrob Agents Chemother. 2005 Jun;49(6):2387-98. doi: 10.1128/AAC.49.6.2387-2398.2005. Antimicrob Agents Chemother. 2005. PMID: 15917538 Free PMC article.
-
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003. Paediatr Drugs. 2001. PMID: 11706924 Review.
-
In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.Antimicrob Agents Chemother. 1998 Aug;42(8):2070-3. doi: 10.1128/AAC.42.8.2070. Antimicrob Agents Chemother. 1998. PMID: 9687409 Free PMC article.
-
The new macrolides. Azithromycin and clarithromycin.West J Med. 1994 Jan;160(1):31-7. West J Med. 1994. PMID: 8128699 Free PMC article. Review.
-
The Mycobacterium avium complex.Clin Microbiol Rev. 1993 Jul;6(3):266-310. doi: 10.1128/CMR.6.3.266. Clin Microbiol Rev. 1993. PMID: 8358707 Free PMC article. Review.